An Analysis of the PANORAMA 1 Trial

Angela Dispenzieri, MD
Published Online: July 11, 2014
Angela Dispenzieri, MD, a professor of medicine in the division of hematology at the Mayo Clinic, discusses the results of the PANORAMA 1 trial: a randomized, double-blind, phase III study of panobinostat or placebo plus bortezomib and dexamethasone in relapsed or relapsed and refractory multiple myeloma.

Clinical Pearls:
  • This was a positive study in terms of progression-free survival. The progression-free survival was about 4 months better in the panobinostat arm.
  • There were significantly more grade 3 toxicities, such as diarrhea, thrombocytopenia and fatigue, in the panobinostat arm.
  • There is no signal in terms of better overall survival.


Related Articles
Denise A. Yardley, MD, from Sarah Cannon Research Institute, discusses toxicities associated with treatment with PI3K inhibitors for breast cancer.
Anti-CD38 monoclonal antibodies continue to demonstrate promise and generate excitement that a new treatment paradigm could be on the horizon for patients with multiple myeloma.
Shaji Kumar, MD, professor of medicine, Mayo Clinic, discusses the results of the phase III ASPIRE trial.
Immunotherapy is the only alternative to chemotherapy and radiation for the treatment of advanced-stage tumors and recent research has shown a correlation between weight and the toxicity of these immunotherapies.
JTT Articles
Bromodomain Inhibitor Shows Activity in Hematologic Malignancies
Management of Hepatocellular Cancer
External Resources

AJMC
HCPLive
OncLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Internal Resources

Articles
Fellows
Publications
Targeted Communications
Resources
Connect With Us:

About Us
Advertise
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright TargetedOnc 2013
Intellisphere, LLC. All Rights Reserved.